Publications

All Scientific Authors are listed in order of contribution with the exception of the corresponding author 

All Scientific Authors are listed in order of contribution with the exception of the corresponding author

*  indicates corresponding/senior author

underlined authors indicate undergraduate students

94. De Novo Design, Synthesis, and Mechanistic Evaluation of Short Peptide That Mimic Heat Shock Protein 27 Activity 

Jessica Kho, P Chi Pham, Suhyeon Kwon, Alana Y Huang, Joel P Rivers, Huixin Wang, Heath Ecroyd, W  Alexander Donald, Shelli R McAlpine*

ACS Med. Chem. Lett. V12, p713-719, 2021 doi.org/10.1021/acsmedchemlett.0c00609

93.  Using NMR to identify binding regions for N and C-terminal Hsp90 inhibitors  using Hsp90 domains.

Jeanette R. McConnell, H. Jane Dyson*, Shelli R. McAlpine*.  RSC Medicinal Chemistry V12, p410-415, 2021

92. Cyclic Peptides as drugs for intracellular targets: The next frontier in peptide therapeutic development Laura K. Buckton, Marwa N. Rahimi, and Shelli R.

McAlpine *

Chem. Eur. J. V27, V27, p1487-1513, 2021, DOI: 10.1002/chem.201905385

91.  Real Time monitoring of peptide delivery in vitro using high payload pH responsive nanogels

Shegufta Farazi, Fan Chen, Henry Foster, Raelene Boquiren, Shelli R. McAlpine, and Robert Chapman* Polym. Chem.V11, p425-432 2020, DOI: 10.1039/C9PY01120J

90.  C-terminal Hsp90 inhibitors block the HIF-1 hypoxic response by degrading HIF-1a through the oxygen-dependent degradation pathway

Nalin Kataria, Chloe-Anne Martinez, Bernadette Kerr, Samantha S. Zaiter, Monica Morgan, Shelli R. McAlpine and Kristina M Cook*    Cell. Physiol. Biochem V53, p480-495  2019 DOI: 10.33594/000000152.

89.  Polymer mediate transport of the Hsp90 inhibitor LB76, a polar resulting cyclic peptide, produces an Hsp90 cellular phenotype

Marwa N. Rahimi, Henry G. Foster, Shegufta N. Farazi, Robert Chapman*, and Shelli R. McAlpine*  Chem Commun, V55, p4515-4518 2019   DOI:10.1039/C9CC00890J 

88.  Delivering bioactive cyclic peptides that target Hsp90 as prodrugs

Yuantao Huo, Laura K. Buckton,  Jack L. Bennett, Eloise C. Smith, Frances, L. Byrne, Kyle L. Hoehn, Marwa N. Rahimi, and Shelli R. McAlpine*  J. Enzyme Inhib. Med. Chem.V34, p728-739, 2019 DOI:  10.1080/14756366.2019.1580276

87.  Protein-protein inhibitors designed de-novo to target the C-terminus of  Hsp90 block co-chaperone activity

Marwa N. Rahimi and Shelli R. McAlpine* Chem. Commun. V55, p846-849, 2019 DOI: 10.1039/C8CC07576J

86.  Designing de novo small molecules that control Heat shock protein 70 within the chaperone machinery

Samantha S. Zaiter, Yuantao Huo, Fong Ying Tiew, Jason E. Gestwicki, and Shelli R. McAlpine * J. Med. Chem. V62, p742-761, 2019 DOI:10.1021/acs.jmedchem.8b01436

85. Nanoparticles for bioapplications: Study of the cytotoxicity of water dispersible CdSe(S) and CdSe(S)/ZnO Quantum Dots

F Mirnajafizadeh, D. Ramsey, S. R. McAlpine, F. Wang, P. Reece, J. Stride* Nanomaterials, V9 p465 2019 DOI: 10.3390/nano9030465   

84.  Functionalization of Quinazolin-4-Ones Part 3: Synthesis, structures, elucidation DNA-PK, PI3K and cytotoxicity of novel 8-aryl-2-morpholino-quinazolin-4-ones

Jacob T. Heppella, MD. Amirul Islamc Shelli R McAlpine and Jasim M. A. Al-Rawi* J. Heterocycl. Chem., V56, p124-142 2019 DOI: 10.1002/jhet.3385 2019

83.  Hsp90 mediates membrane deformation and exosome release Elsa Lauwers,

*Yu-Chung Wang, Rodrigo Gallardo, Rob Van der Kant, Emiel Michiels, Jef Swerts, Pieter Baatsen, Samantha S. Zaiter, Shelli R. McAlpine, Natalia V. Gounko, Frederic Rousseau, Joost Schymkowitz, and Patrik Verstreken* Molecular Cell V71, p689-702, e9 2018 DOI: 10.1016/j.molcel.2018.07.016

82.  Converting Polar cyclic peptides into cell permeable molecules using N-methylation

Leo L. H. Lee, Laura K. Buckton* and Shelli R. McAlpine* Peptide Science, V110, e24063. 2018 DOI: 10.1002/pep2.24063

81.  Improving the cell permeability of polar cyclic peptides by replacing residues with alkylated amino acids, asparagines, and D-amino acids

Laura K. Buckton and Shelli R. McAlpine* Org. Lett. V20, p506-509, 2018

80.  Synthesis and structure-activity relationships of inhibitors that target the C-terminal MEEVD on  Heat shock protein 90 (Hsp90)

Marwa N. Rahimi, Laura K. Buckton, Samantha S. Zaiter, Jessica Kho, Vickie Chan, Aldwin Guo, Jenane Konesan, SuHyeon Kwon, Lok K. O. Lam, Michael F. Lawler, Michael Leong, Gabriel D. Moldovan, David A. Neale, Gillian Thornton, and Shelli R. McAlpine* ACS Med. Chem. Lett. V9 p73-77 2018 

79.  RITA mimics: Synthesis and mechanistic evaluation of asymmetric linked Trithiazoles

Adrian L. Pietkiewicz,†  Yuqi Zhang,† Marwa N. Rahimi, Michael Stramandinoli, Matthew Teusner, and Shelli R. McAlpine* ACS Med. Chem. Lett. V8 p401-406 2017   

78.  Redefining the phenotype of Heat shock protein 90 (Hsp90) inhibitors

Yao Wang, Yen Chin Koay, and Shelli R. McAlpine* Chem. Eur. J. V23  2010-2013 2017

 77.  How selective are Hsp90 inhibitors for cancer cells over normal cells?

Yao Wang, Yen Chin Koay, and Shelli R. McAlpine* ChemMedChem V12 p353-357 2017

76. Allosteric Modulators of Heat Shock Protein 90 (HSP90)

Yen Chin Koay and Shelli R. McAlpine * RSC Drug discovery series: “Allosterism in Drug Discovery” DOI: 10.1039/9781782629276, p404-426

 75.  Reinventing Hsp90 inhibitors: Blocking C-terminal binding events to Hsp90 using dimerized inhibitors

Yen Chin Koay, Hendra Wahyudi Shelli R. McAlpine* Chem. Eur. J. V22, p18572-18582 2016

74.  A novel class of Hsp90 C-terminal modulators have preclinical efficacy in prostate tumor cells without induction of a heat shock response

Heather K. Armstrong, Yen Chin Koay, Swati Irani, Rajdeep Das, Zeyad D. Nassar, The Australian Prostate Cancer Bio resource, Luke A. Set, Margaret M. Centenera, Shelli R. McAlpine* and Lisa A. Butler* The Prostate V76, p1546-1559 2016   

73.  Hydrothermal synthesis of highly luminescent blue-emitting ZnSe(S) quantum dots exhibiting low toxicity

Fatemeh Mimajafizadeh, Deborah Ramsey, Shelli R. McAlpine, Fan Wang, Peter Reece, and John Arron Stride*, Mat. Science and Eng. C V.64, p167-172 2016

72.  Hitting a moving target: How does an N-Methyl group impact biological activity?

Yen Chin Koay, Nicole L. Richardson, Samantha S. Zaiter, Jessica Kho, Sheena Y.Nguyen, Daniel H. Tran, Ka Wai Lee, Laura K. Buckton, , and Shelli R. McAlpine* ChemMedChem. V11, p881-892 2016

71.  The first report of direct inhibitors that target the C-terminus MEEVD region on heat shock protein 90

Laura K. Buckton, Hendra Wahyudi, and Shelli R. McAlpine* Chem. Commun. V52, p501-504 2016

70. Hsp47: The new heat shock protein therapeutic target

George Sharbeen, Shelli R. McAlpine, Phoebe Phillips* Springer Books: “Heat shock Proteins: Success Stories” 2016   DOI: 10.1007/7355_2015_89

69. Are some Hsp90 therapies more effective than others? Evaluating dual Hsp90 and Hsp70 inhibition as an anticancer therapy

Laura K Buckton, Yao Wang, Jeanette R. McConnell, and Shelli R. McAlpine* Springer Books: “Heat shock Proteins: Success Stories” 2016 DOI: 10.1007/7355_2015

68. Heat shock protein 27: structure, function, cellular Role and inhibitors

Rashid Mehmood* and Shelli R. McAlpine* Springer Books: “Heat shock Proteins: Success Stories” 2016 DOI: 10.1007/7355_2015_94

67. Targeting the c-terminus of heat shock protein 90 as a cancer therapy

Jeanette R McConnell, Yao Wang, Shelli R. McAlpine* Springer Books: “Heat shock Proteins: Success Stories” 2016 DOI: 10.1007/7355_2015_93

66.  Synthesis of the natural product Marthiapeptide A

Yuqi Zhang, Amirul Islam, and Shelli R. McAlpine*  Org. Lett. V17, p5149-5151 2015 

65.  Blocking the heat shock response and depleting HSF-1 levels through heat shock protein 90 (hsp90) inhibition: A significant advance over current chemotherapies

Yen Chin Koay, Jeanette R. McConnell, Yao Wang, and Shelli R. McAlpine* RSC Advances V5, 59003-59013 2015

64.  Regulating the master regulator: controlling heat shock factor-1 as a chemotherapeutic

Jeanette R. McConnell, Laura K Buckton, and Shelli R. McAlpine* Bioorg. Med. Chem Lett. V25, 3409-3414  2015

63.  Thioimidazoline based compounds reverse glucocorticoid resistance in acute lymphoblastic leukemia cells

Cara Toscan, Marwa Rahimi, Mohan Bhadbhade, Russell Pickford, Shelli R. McAlpine* and Richard Lock* Org. Biomol. Chem. V13, 6299-6312 2015

62.  Predicting the unpredictable: recent examples of biologically active heterocycle-containing macrocycles

Hendra Wahyudi and Shelli R. McAlpine* Bioorganic Chem. V60, 74-97 2015

61.  Activation of the Nuclear Factor kB inducing kinase as a mechanism of  beta cell failure in obesity

Elisabeth K. Malle, Nathan W. Zammit, Stacey N. Walters, Yen Chin Koay, Jianmin, Wu,  Bernice, M. Tan, Jeanette E. Villanueva, Robert Brink, Tom Loudovaris, James Cantley, Shelli R. McAlpine, Daniel Hesselson, Shane T. Grey*  J. Exp. Med., V212, 1239-1254 2015

60.  C-terminal heat shock protein 90 modulators produce desirable oncogenic properties

Yao Wang and Shelli R. McAlpine* Org. Biomol. Chem, V13, 4627-4631  2015

59.  Combining an Hsp70 inhibitor with either an N-terminal and C-terminal hsp90 inhibitor produces mechanistically distinct phenotypes

Yao Wang and Shelli R. McAlpine*   Org. Biomol. Chem. V13, 3691-3698 2015

58.  Heat shock protein 90 inhibitors: will they ever succeed as chemotherapeutics?

Yao Wang, and Shelli R. McAlpine* Future Med. Chem. V7, 2, 87-90 2015 

57.  Regulating the cytoprotective response in cancer cells using simultaneous inhibition of Hsp90 and Hsp70

Yao Wang, and Shelli R. McAlpine* Org. Biomol. Chem. V13, 2108-2116  2015

56.  Design, Synthesis and anticancer activity of linked azoles

Amirul Islam, Yuqi Zhang, Yao Wang, and Shelli R. McAlpine* Med. Chem. Comm. V6, 300-305 2015

55.  The fungal natural product (1S, 3S)-austrocortirubin induces DNA damage via a mechanism unique from other DNA damaging agents

Yao Wang∞,Md. Amirul Islam∞, Rohan A. Davis, and Shelli R. McAlpine* Bioorg. Med. Chem Lett. V25, 249-253  2015

54.  N-terminal and C-terminal modulation of hsp90 produce dissimilar phenotypes

Yao Wang and Shelli R. McAlpine* Chem. Comm.  V51, 1410-1413 2015  COVER OF THE JOURNAL

53. HSP90 inhibitors and conjunctival melanoma M

Madigan,* X. Quah, S. McAlpine, and R. M. Conway Acta Ophthalmologica. V92, s253 2014

52. Synthesis of macrocycles that inhibit protein synthesis: stereochemistry and structural based studies on sanguinamide B derivatives

Adrian L Pietkiewicz, Hendra Wahyudi, Jeanette, R, McConnell, and Shelli R. McAlpine * Tetrahedron Lett. V55, 6979-6982 2014. COVER OF THE JOURNAL

51.  Chemically accessible hsp90 inhibitor that does not induce a heat shock response

Yen Chin Koay, Jeanette R. McConnell, Yao Wang, Seong Jong Kim, Laura K. Buckton, Flora Mansour and Shelli R. McAlpine* ACS Med. Chem. Lett. V5, 771-776, 2014

50. Synthesis and cytotoxicity of sanguinamide B analogs: identification of an active macrocyclic conformation

Hendra Wahyudi, Worawan Tantisantisom, and Shelli R. McAlpine* Tetrahedron Lett. V55, 2389-2393, 2014 COVER OF THE JOURNAL

49. Recent Advances in Macrocyclic Hsp90 Inhibitors

Deborah Ramsey, R.R. A Kitson, J. I Levin, C. J Moody*, and S. R. McAlpine*  RSC Books: Macrocycles in Drug Discovery: DOI:10.1039/9781782623113-00037; p37-77 2014

48. A Heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing a heat shock response

Jeanette R. McConnell, Leslie D. Alexander, and Shelli R. McAlpine*  Bioorg. Med. Chem Lett. V24, p661-666, 2014

47. Utilizing a Dimerization strategy to inhibit the dimer protein Hsp90: Synthesis and biological activity of a sansalvamide

A dimer Hendra Wahyudi, Yao Wang, and Shelli R. McAlpine*  Org. Biomol. Chem. V12, p765-773 2014

46. Total synthesis and biological activity of the natural product Urukthapelstatin A

Chun Chieh Lin, Worawan Tantisantisom, and Shelli R. McAlpine*  Org. Lett.  V15, p3574-3577, 2013

45. Mechanism of action for a novel macrocycle: a small molecule inhibitor of the ribosome machinery

Worawan Tantisantisom, Deborah M. Ramsey, and Shelli R. McAlpine* Org. Lett.  V15, p4638-4641, 2013

44.  Effectively delivering a drug using star polymers: Improving solubility of a unique hsp90 inhibitor Seong Jong Kim, Deborah M.



Ramsey, Cyrille Boyer, Thomas Davis, and  Shelli R. McAlpine* ACS Med. Chem. Lett  V4, p915-920, 2013

43. Novel Marine Natural Products that target the gram-positive Cell Wall

Deborah M. Ramsey,* Amirul Islam, Rohan A. Davis, Cynthia B. Whitchurch, Lynne Turnbull  and Shelli R. McAlpine*  Bioorg. Med. Chem Lett. V23, p4862-4866, 2013

42. A potential Rhodium Cancer Therapy: studies of a cytotoxic organorhodium (I) complex that binds DNA

Jeanette R. McConnell, Dimple P. Rananaware, Deborah M. Ramsey, Kai N. Buys, Marcus L. Cole and  Shelli R. McAlpine*  Bioorg. Med. Chem Lett. V23, p2527-2531   2013           

41. Heat shock proteins 27, 40, and 70 as combinational therapeutic targets

Jeanette R. McConnell and Shelli R. McAlpine* Bioorg. Med. Chem. Lett. V23, p1923-1928, 2013

40. An efficient synthetic route for synthesizing macrocycles that contain heterocycles: Solid Phase versus Solution Phase Synthesis

Seong Jong Kim and Shelli R. McAlpine* Molecules V18, p1111-1121  2013

39. A structure-activity relationship study on multi-heterocyclic molecules: two linked thiazoles are required for cytotoxic activity

Seong Jong Kim, Chun Chieh Lin, Chung-Mao Pan, Dimple P. Rananaware, Deborah M. Ramsey, and Shelli R. McAlpine* Med. Chem. Comm.  V4 , p406-410, 2013

38. Halting Metastasis through CXCR4 inhibition

Deborah M. Ramsey* and Shelli R. McAlpine* Bioorg. Med. Chem. Lett. V23, p20-25, 2013

37. Synthesis, structure-activity analysis, and biological evaluation of structurally related conformational isomers

Hendra Wahyudi, Worawan Tantisantisom, Xuechao Liu, Deborah M. Ramsey, Erinprit K. Singh, and Shelli R. McAlpine*   J. Org. Chem. v77, p10596-10616, 2012

36. A new Hsp90 inhibitor that exhibits a novel biological profile

Deborah M. Ramsey, Jeanette R. McConnell, Leslie D. Alexander, Kaishin W. Tanaka, Chester M. Vera, and Shelli R. McAlpine* Bioorg. Med. Chem. Lett. v22, p3287-3290, 2012

35. Progress towards the synthesis of Urukthapelstatin A and two analogs

Chung-Mao Pan, Chun-Chieh Lin, Seong Jong Kim, Robert P. Sellers, and Shelli R. McAlpine* Tetrahedron Lett., v53, p4065-4069, 2012

34. Total Synthesis of Natural Product trans,trans- Sanguinamide B and its structurally related conformational isomers

Erinprit K. Singh, Deborah M. Ramsey, and Shelli R. McAlpine* Org. Lett. v14, p1198-1201, 2012

33. Synthesis of Sansalvamide A Peptidomimetics: Triazole Oxazole, Thiazole,and Pseudoproline containing compounds

Melinda R. Davis, Erinprit K. Singh, Hendra Wahyudi, Leslie D. Alexander, Joseph Kunicki, Lidia A. Nazarova, Kelly A. Fairweather, Andrew Giltrap, Katrina A. Jolliffe, and Shelli R. McAlpine*  Tetrahedron, v68, p1029-1051, 2012

32. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins

Veronica C Ardi, Leslie D. Alexander, Victoria Johnson, and Shelli R. McAlpine* ACS Chem. Biol. v6, p1357-1367, 2011

31. Small Molecule Inhibitors of Hsp90’s Conformational Changes

Leslie D. Alexander, James Partridge, David Agard, and Shelli R. McAlpine* Bioorg. Med. Chem. Lett. v21, p7068-7071, 2011

30. Synthesis and Evaluation of Biotinylated Sansalvamide A Analogs and their modulation of Hsp90

Joseph Kunicki, Mark Petersen, Leslie D. Alexander, Veronica C. Ardi, Jeanette R. McConnell, and Shelli R. McAlpine* Bioorg. Med. Chem. Lett, v21, p4716-4719, 2011

29.  A third generation of Sansalvamide A derivatives: Design and synthesis of Hsp90 inhibitors

Robert P. Sellers, Leslie D. Alexander, Victoria A. Johnson, Chun-Chieh Lin, Jeremiah Savage,  Ricardo Corral, Jason Moss, Tim S. Slugocki, Erinprit K. Singh, Melinda R. Davis, Suchitra Ravula,  Jamie E. Spicer, Jenna L Oelrich, Andrea Thornquist, Chung-Mao Pan, and Shelli R. McAlpine* Bioorg. Med. Chem. v18, p6822-6856 2010

28. Histone deactylace inhibitors: Synthesis of cyclic tetrapeptides & their triazole analogs

Erinprit K. Singh, Lidia A. Nazarova, Stephanie A. Lapera, Leslie D. Alexander and Shelli R. McAlpine* Tetrahedron Lett. v51, p4357-4360 2010

27.  Macrocyclic inhibitors of Hsp90

Victoria A. Johnson, Erinprit K. Singh,  Lidia A. Nazarova, Leslie D. Alexander, and Shelli R. McAlpine* Curr. Top. Med. Chem. v23, p1380-1402 2010

26. Mechanistic studies of Sansalvamide A-amide:An allosteric modulator of Hsp90

Robert C. Vasko, Rodrigo A. Rodriguez, Christian Cunningham, Veronica Ardi, David Agard, and Shelli R. McAlpine* ACS Med. Chem. Lett. v1, p4-8  2010 

25. Evaluation of Di-Sansalvamide A derivatives: synthesis, SAR, and Mechanism of action

Leslie D. Alexander, Robert P. Sellers, Melinda R. Davis, Veronica C. Ardi, Victoria A. Johnson,  Robert C. Vasko and Shelli R. McAlpine* J. Med. Chem. v52, p7927-7930 2009

24. A comprehensive study of Sansalvamide A derivatives: the structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines

Po-Shen Pan, Robert C. Vasko, Stephanie A. Lapera, Victoria A. Johnson, Robert P. Sellers,  Chun-Chieh Lin, Chung-Mao Pan, Melinda R. Davis, Veronica C. Ardi and Shelli R. McAlpine*  Bioorg. Med. Chem.,  v17,  p5806-5825 2009

23. Structure-activity relationships of Sansalvamide A derivatives and their mechanism of action  in the pancreatic cancer cell line PL-45

Rodrigo A. Rodriguez, Po-Shen Pan, Robert C. Vasko, Chung-mao Pan, William Disman, and Shelli R. McAlpine* J. Mex. Chem. Soc.,  v52,  p201-211, 2008

22. Conformational based design of macrocycles as antitumor agents

Erinprit K. Singh, Robert P. Sellers, Leslie D. Alexander and Shelli R. McAlpine*  Curr. Opin. Drug Discovery Dev., v11, p544-552, 2008

21.  Synthesis and biological evaluation of Histone Deacetylates inhibitors that are based on the FR235222 scaffold

Erinprit Singh, Suchitra Ravula, Chung-mao Pan, Po-Shen Pan, Robert C. Vasko, Stephanie A. Lapera, Sujith, Mary Kay Pflum, and Shelli R. McAlpine*  Bioorg. Med. Chem. Lett,v18, p2549-2554, 2008

20. Synthesis and cytotoxicity of a new class of potent decapeptide macrocycles

Melinda R. Davis, Thomas J. Styers, Rodrigo A. Rodriguez, Po-Shen Pan, Robert C. Vasko, and Shelli R. McAlpine* Org. Lett., v10, p177-180, 2008

19. A comprehensive study of Sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines.

Katerina Otrubova, Gerald H. Lushington, David Vander Velde, Kathleen L. McGuire, and Shelli R. McAlpine*  J. Med. Chem., v51, p530-544, 2008

18. Identification of compounds potent against pancreatic cancer cell lines

Po-Shen Pan, Kathleen L. McGuire, and Shelli R. McAlpine* Bioorg. Med. Chem. Lett., v17, p5072, 2007

17. A novel platform targeting drug-resistant colon cancers

Katerina Otrubova, Kathleen L. McGuire and Shelli R. McAlpine* J. Med. Chem. v50, p1999- 2002, 2007

16. Synthesis of second generation Sansalvamide A derivatives: Novel Templates as Potential Anti-tumor Agents

Rodrigo A. Rodriguez, Po-Shen Pan, Chung-Mao Pan, Suchitra Ravula,  Stephanie Lapera, Erin Singh, Thomas J. Styers, Julia Cajica, Joseph D. Brown, Emily Parry, Katerina Otrubova, and Shelli R. McAlpine* J. Org. Chem., v72, p1980-2002, 2007

15. Synthesis of Sansalvamide A derivatives and their cytotoxicity in colon cancer cell line HT-29

Thomas J. Styers, Ahmet Kekec, Rodrigo Rodriguez, Joseph D. Brown, Julia Cajica, Chris L. Carroll, Po-Shen Pan,  Irene Medina, Ricardo Corral, Jennifer V. C. Johnston, Emily Parry, Stephanie Lapera, Katerina Otrubova, Kathleen L. McGuire,* and Shelli R. McAlpine* Bioorg. Med. Chem.,  v14, p5625-5631, 2006

14. Novel Antibiotics: C-2 symmetrical macrocycles affecting Holliday Junction DNA processing

Po-Shen Pan, Fiona A. Curtis, Chris L. Carroll, Irene Medina, Lisa A. Liotta, Gary J. Sharples, and Shelli R. McAlpine* Bioorg. Med. Chem.,  v14, p4731-4739, 2006

13. Synthesis and novel structure-activity relationships of potent

Sansalvamide A derivatives Katerina Otrubova, Thomas J. Styers, Po-Shen Pan, Rodrigo Rodriguez, Kathleen L. McGuire,* and Shelli R. McAlpine* Chem. Commun. p1033-1034, 2006

12. Synthesis of novel Sansalvamide A Derivatives via new, high yielding macrocyclization conditions

Thomas J. Styers, Rodrigo Rodriguez, Po-Shen Pan, and Shelli R. McAlpine* Tetrahedron Lett., v47, p515-517, 2006

11. Synthesis of novel anti-tumor agents: Sansalvamide A derivatives

Chris L. Carroll, Jennifer V. C. Johnston, Ahmet Kekec, Joe Brown, Emily Parry, Julia Cajica, Irene Medina, Kristina M. Cook, Po-Shen Pan, and Shelli R. McAlpine* Org. Lett., v7 p3481-3484, 2005

10. Novel Antibiotics: second generation macrocyclic peptides designed to trap holliday junction

Lisa A. Liotta, Irene Medina, Jennifer L. Robinson, Chris L. Carroll, Po-Shen Pan, Ricardo Corral, Jennifer V. C. Johnston, Kristina M. Cook, Fiona A. Curtis, Gary J. Sharples and Shelli R. McAlpine* Tetrahedron Lett.,  v45, p8447-8450 2004 

9.   Understanding Diseases via Receptor Regulation

Shelli R. McAlpine Chem. and Biol., v11, p157-158 2004 

8.   A progressive synthetic strategy for Class B Synergimycins

Jennifer L. Robinson, Rachel E. Taylor, Lisa A. Liotta, Megan L. Bolla Enrique V. Azevedo, Irene Medina, and Shelli R. McAlpine* Tetrahedron Lett., v45, p2147-2150 2004

 7.   Novel Antibiotics: Macrocyclic Peptides Designed to Trap Holliday Junctions

MeganL. Bolla, Enrique V. Azevedo, Jason M.  Smith, Rachel E. Taylor, Dev K. Ranjit, Anca M.  Segall, and Shelli R. McAlpine* Org. Lett., v5, p109-112 2003

 6.   Determination of Functional Group Distribution within Rasta Resins Utilizing Optical Analysis Shelli R. McAlpine*, Craig W.

Lindsley, John C. Hodges*, D. M. Leonard, G. F. Filzen  J. Comb. Chem.,  v3, p.1-5 2001

Graduate and Post-doctoral publications

5.   Visualizing Functional Group Distribution in Solid Support Beads using Optical Analysis

Shelli R. McAlpine,* Stuart L. Schreiber, Chem.- Eur. J., v5, p.3528 1999

4.   Studies of Naphthyl-Substituted –Cyclodextrins.  Self-Aggregation and Inclusion of External Guests

Shelli R. McAlpine, Miguel A. Garcia-Garibay* J. Am. Chem. Soc., v120, p. 4269 1998

3.   C32-O-Imidazol-2-yl-methyl Ether Derivatives of the Immunosuppressant Ascomycin with Improved Therapeutic Potential

M. T. Goulet*, S. R. McAlpine; M. Staruch;, S. Koprak, F. J. Dumont, J. G. Cryan, G. J. Wiederrecht, R. Rosa, M. B. Wilusz, L. B. Peterson, M. J. Wyvratt,  W. H. Parsons Bioorg. Med. Chem. Lett., v8, p.2253 1998

 2.   Binding Studies of Adamantanecarboxylic Acid and a Naphthyl-Bound -Cyclodextrinby Variable Temperature 1H NMR

S. R. McAlpine, M. A. Garcia-Garibay* J. Org. Chem., v61, p. 8307 1996

 1.   Inside-Outside Isomerism of -Cyclodextrin Covalently Linked with a Naphthyl Group  S. R. McAlpine, M. A. Garcia-Garibay*

J. Am. Chem. Soc., v118, p. 2750-2751 1996

3.   C32-O-Imidazol-2-yl-methyl Ether Derivatives of the Immunosuppressant Ascomycin with Improved Therapeutic Potential

M. T. Goulet*, S. R. McAlpine; M. Staruch;, S. Koprak, F. J. Dumont, J. G. Cryan, G. J. Wiederrecht, R. Rosa, M. B. Wilusz, L. B. Peterson, M. J. Wyvratt,  W. H. Parsons Bioorg. Med. Chem. Lett., v8, p.2253 1998

Other Publications

Life as an academic: being a female assistant professor in chemistry

Shelli R. McAlpine American Chemical Society: Gladly We Teach, p57 2006

Shelli R. McALpine, PhD., Visiting Professor at University of California, Irvine and Handling Editor Bioorganic Chemistry (Elsevier)